BioCentury
ARTICLE | Company News

Incyte, Novartis deal

December 7, 2009 8:00 AM UTC

Incyte granted Novartis exclusive rights to develop and commercialize two compounds. Novartis received ex-U.S. rights to Incyte's lead compound, oral INCB18424. The janus kinase-1 (JAK-1) and JAK-2 inhibitor is in Phase III testing for myelofibrosis and Phase II testing for advanced polycythemia vera and essential thrombocythemia. Incyte retains rights to topical INCB18424, which is in Phase IIb testing for psoriasis.

Novartis also received worldwide rights to INCB28060, an oral c-Met proto-oncogene (MET, HGFR) inhibitor in preclinical testing for cancer. Incyte retained an option to co-promote INCB28060 in the U.S. Novartis will be responsible for development of INCB28060 after completion of the Phase I trial. ...